Skip to main navigation Skip to search Skip to main content

Epidemiology, ventilation, and outcomes of acute respiratory failure in immunocompromised patients from 103 intensive care units in 26 countries: a retrospective observational study

  • Efraim III Investigators
  • Université Paris Cité
  • Washington University St. Louis
  • University of Barcelona
  • Hamad Medical Corporation
  • Weill Cornell Medicine-Qatar
  • HBKU College of Health and Life Sciences
  • Université libre de Bruxelles
  • Homi Bhabha National Institute
  • Université Grenoble Alpes
  • University of Cologne
  • Universidad de la República
  • University of Texas MD Anderson Cancer Center
  • Vall d'Hebron Research Institute
  • Hôpital Édouard Herriot
  • Médecine Intensive et Réanimation – Hautepierre
  • Zhejiang University
  • CHRU de Lille
  • King Saud bin Abdulaziz University for Health Sciences
  • General Hospital of Athens
  • General Hospital of Thessaloniki “G Papanikolaou”
  • Fondazione Policlinico Universitario A. Gemelli IRCCS
  • Institut Paolli-Calmettes
  • CHU de Toulouse
  • University of Liege
  • Hôpital Charles Nicolle
  • Université d'Angers
  • Charles University
  • Institut Gustave Roussy
  • Sorbonne Université
  • Mayo Clinic Rochester, MN
  • University Health Network
  • Hôpital Nord AP-HM
  • Gazi University
  • Memorial Sloan-Kettering Cancer Center
  • Medical University of Vienna
  • Hospices civils de Lyon
  • King's College Hospital NHS Foundation Trust
  • Medical University of Graz
  • University of Zurich
  • Radboud University Nijmegen
  • Medical Intensive Care Unit
  • Department of Neurology
  • NOVA University Lisbon
  • University of Glasgow
  • University of Copenhagen

Research output: Contribution to journalArticlepeer-review

Abstract

Background Acute hypoxaemic respiratory failure (ARF) is the leading cause of intensive care unit (ICU) admission among immunocompromised patients. However, contemporary data regarding the epidemiology, management, and outcomes of ARF in this population remain scarce. We aimed to identify predictors of mortality and intubation in immunocompromised patients admitted to the ICU with ARF. Methods This retrospective observational study was conducted in 103 ICUs in 26 countries. Adults (>= 18 years) with ARF and immunodeficiency were eligible for inclusion. Patient data, including information on the nature of underlying immunosuppression, the cause of ARF, and the oxygenation strategy, were obtained from electronic medical records or medical charts. The primary outcome was to report 30-day mortality and identify associated factors in patients with complete data for all variables. Cox proportional hazards models were used to identify variables associated with mortality, and differences between groups were compared with chi 2 tests or two-sided Wilcoxon rank-sum tests, with p values of less than 0 & centerdot;05 considered significant. Findings 9854 immunocompromised patients with ARF admitted to participating ICUs between Jan 1, 2017, and Dec 31, 2023, were included in the study. The median age was 64 years (IQR 54-71); 3941 (40 & centerdot;0%) patients were female and 5913 (60 & centerdot;0%) were male. The main causes of immunodeficiency were a haematological malignancy (4759 [48 & centerdot;3%] of 9854 patients) or solid malignancy (3818 [38 & centerdot;7%] patients). Infection was the leading cause of ARF (6610 [62 & centerdot;0%] of 9854 patients); 5288 (53 & centerdot;7%) patients had more than one contributing cause of ARF, and no cause was identified in 1490 (15 & centerdot;1%) patients. The median partial pressure of oxygen in arterial blood (PaO2)/fractional concentration of oxygen in inspired air (FiO2) ratio was 198 [IQR 141-208]. The 30-day mortality rate was 47 & centerdot;3% (4662 patients). Predictors of higher mortality were older age (hazard ratio 1 & centerdot;01 [IQR 1 & centerdot;00-1 & centerdot;02]), higher Charlson Comorbidity Index score (1 & centerdot;04 [1 & centerdot;01-1 & centerdot;07]), higher Frailty Index score (1 & centerdot;22 [1 & centerdot;16-1 & centerdot;28]), longer time from hospital to ICU admission (1 & centerdot;02 [1 & centerdot;01-1 & centerdot;03]), higher respiratory rate (1 & centerdot;02 [1 & centerdot;02-1 & centerdot;03]), coma at ICU admission (2 & centerdot;04 [1 & centerdot;72-2 & centerdot;43]), invasive fungal infection as cause of ARF (1 & centerdot;82 [1 & centerdot;45-2 & centerdot;28]), disease-specific infiltrates (1 & centerdot;73 [1 & centerdot;32-2 & centerdot;26]), unidentified cause of ARF (2 & centerdot;16 [1 & centerdot;74-2 & centerdot;68]), and use of vasoactive drugs (2 & centerdot;45 [2 & centerdot;10-2 & centerdot;86]) or renal replacement therapy (2 & centerdot;07 [1 & centerdot;74-2 & centerdot;48]). Protective factors included receipt of a solid organ transplant (0 & centerdot;62 [0 & centerdot;49-0 & centerdot;79]), systemic vasculitis or connective tissue disease (0 & centerdot;61 (0 & centerdot;47-0 & centerdot;78]), higher PaO2/FiO2 ratio (0 & centerdot;78 [0 & centerdot;72-0 & centerdot;84]), receipt of high-flow nasal oxygen therapy (0 & centerdot;78 [0 & centerdot;64-0 & centerdot;95]), and cardiogenic pulmonary oedema (0 & centerdot;67 [0 & centerdot;51-0 & centerdot;89]). Interpretation In tThese findings could improve outcomes by informing timely clinical decisions, goals-of-care discussions, and management in this vulnerable population. Copyright (c) 2026 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Original languageEnglish
Pages (from-to)395-404
Number of pages10
JournalThe Lancet Respiratory Medicine
Volume14
Issue number5
DOIs
Publication statusPublished - May 2026

Keywords

  • Critically-ill
  • Hematology
  • Malignancies
  • Nasal cannula
  • Noninvasive ventilation
  • Oxygen

Fingerprint

Dive into the research topics of 'Epidemiology, ventilation, and outcomes of acute respiratory failure in immunocompromised patients from 103 intensive care units in 26 countries: a retrospective observational study'. Together they form a unique fingerprint.

Cite this